<DOC>
	<DOCNO>NCT01499004</DOCNO>
	<brief_summary>This study explore drug behavior safety follow single dose three different 22 milligram tofacitinib ( CP-690,550 ) modified-release formulation 30 healthy volunteer . These formulation compare 10 milligram tofacitinib ( CP-690-550 ) immediate-release formulation .</brief_summary>
	<brief_title>A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib ( CP-690,550 ) In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male subject and/or healthy female subject nonchildbearing potential . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ; Clinically significant infection within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>tofacitinib</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>modify release</keyword>
	<keyword>Phase 1</keyword>
</DOC>